Abstract Copy number variation (CNV) is a common chromosomal alteration that can occur during in vitro cultivation of human cells and can be accompanied by the accumulation of mutations in coding region sequences. We describe here a systematic application of current molecular technologies to provide a detailed understanding of genomic and sequence profiles of human embryonic stem cell (hESC) lines that were derived under GMP-compliant conditions. We first examined the overall chromosomal integrity using cytogenetic techniques to determine chromosome count, and to detect the presence of cytogenetically aberrant cells in the culture (mosaicism). Assays of copy number variation, using both microarray and sequence-based analyses, provide a detailed view genomic variation in these lines and shows that in early passage cultures of these lines, the size range and distribution of CNVs are entirely consistent with those seen in the genomes of normal individuals. Similarly, genome sequencing shows variation within these lines that is completely within the range seen in normal genomes. Important gene classes, such as tumor suppressors and genetic disease genes, do not display overtly disruptive mutations that could affect the overall safety of cell-based therapeutics. Complete sequence also allows the analysis of important transplantation antigens, such as ABO and HLA types. The combined application of cytogenetic and molecular technologies provides a detailed understanding of genomic and sequence profiles of GMP produced ES lines for potential use as therapeutic agents.
Introduction
The development of cell-based therapeutics for clinical applications will continue to require rigorous quality control of the chromosomal and genetic integrity. The process of in vitro propagation of human cells can often lead to a disruption of DNA integrity whether analyzed at the level of whole genomes, individual chromosomes or at base pair resolution. Trisomies 12 and 17 has been reported in long-term cultures of hESCs (Draper et al., 2004) , while more recently, higher resolution methods for identifying copy number variation (CNV), such as comparative genomic hybridization (CGH) and array-based profiling, have reported a much broader spectrum of chromosomal amplifications and deletions that vary substantially with both cell strain and propagation history (Laurent et al., 2011; Hussein et al., 2011; Lefort et al., 2008; Spits et al., 2008) . Whole genome resequencing is now being applied to the assessment of cultured cells and has shown that induced pluripotent stem (iPS) cell methods can lead to the accumulation of point mutations in the resulting clonal population (Gore et al., 2011) . Similarly, iPS cells can display substantial differences in their epigenetic profiles compared to embryonic stem cells (Lister et al., 2011) .
While the current methodologies for genome and sequence analysis provide unprecedented resolution for identifying potential variance in cell cultures, the impact of any specific variance may not be easily predicted. Aneuploidy is generally considered to be an unambiguous quality control issue for human cell-based therapies given that chromosomal aberrations can result in increased risk of oncogenic transformation (McClendon et al., 2008) . Similarly, rare and common DNA variations that modulate disease risk should be assessed, particularly for genes whose functional disruption can lead to transformation. Of less obvious impact on the safety and performance of cellular therapeutics are smaller scale changes in gene copy number, coding sequence variance, or disease-associated alleles. Sequence variance in the genome occurs predominantly at the level of CNV or single nucleotide variance (SNV) and for cells intended for human therapies, normal genomes can provide a useful comparator.
Here we described a comprehensive analysis of chromosomal and gene variance in 5 human ES cell lines that were derived using GMP compliant methods (Crook et al., 2007) . We first analyzed the overall karyotype using G-banding to ensure overall chromosomal integrity and then used FISH probes to detect the presence of emerging clones with altered chromosomal copy number. Short tandem repeat (STR) fingerprints were derived for each line and can be used to track long-term cultures and derivatives while telomere length analysis confirmed the embryonic potential of these lines for long term propagation. Our review of copy number variation applies two orthogonal methods and then compares the resulting variants to those seen in normal genomes. Similarly, we compare sequence variance directly to normal genomes to achieve a balanced review of nonconservative variance seen in specific gene classes, such as tumor suppressors, and in disease-associated alleles, such as APOE. By each of these measures, early passage cultures of these lines display variance that is entirely consistent with that seen in normal individuals. Finally, we review specific transplantation-related antigens that can now be assessed by sequence-based methods.
Results hES cell culture
The ESI lines described here were derived with GMPcompliant derivation procedures and were initially expanded on human fibroblast feeder cultures (Crook et al., 2007) . We routinely culture hESC lines in ES culture medium (mTeSR1; StemCell Technologies); an assessment of hESC-related cell surface markers showed high level expression in ESI lines cultured on Matrigel (Table S1 ).
Analysis strategy
Our assessment of hESC cultures applied both cell-based and DNA-based analysis to the preparations. Genomic DNA samples are collected for multiple applications, including STR fingerprinting, telomere length analysis, CNV assessment and complete genome sequencing (Fig. 1) . Cell cultures are used for cytogenetic assessment. G-band karyotyping provides an overall review of chromosome count and integrity, and can be particularly useful in defining several chromosomal aberrations, including balanced translocations and inversions, that can be difficult to detect by SNP-based techniques. All 5 ESI lines tested showed a normal human karyotype, with 4 female (XX) and 1 male lineages (Figs. 2A, B) . To better assess culture mosaicism, we applied FISH probes to interphase nuclei that detect the short arm of chromosome 12 (ETV-6) and the centromere of chromosome 17, two of the most widely reported aneuploidies seen in cultured human cells (Meisner and Johnson, 2008) . Although four of five ES cultures had a normal diploid signal pattern for both probes, culture ESI 051 demonstrated three 12p13 (ETV6) signals in 4% OF 200 interphase nuclei, consistent with an emerging clone with trisomy 12 (Figs. 2A, C) . We did not observe copy number variation at the ETV-6 locus for ESI051, using either SNP-based arrays or sequencing-derived methods, as would be expected given the low frequency of these cells in the population. Homogenous assays, such as those applied to DNA prepared from cell culture, have a limited ability to detect low levels of aberrant cells within a culture compared to FISH.
STR fingerprinting has become the international standard procedure for tracking cellular identity (Schweppe et al., 2008) and is particularly useful in manufacturing, where molecular authentication of derivative cell lines is required. Each of the ESI lines provides a unique identifier and as expected, H9 was returned as an identity hit when the STR-based fingerprint was queried against the NIH Embryonic Stem Cell Registry (http://grants.nih.gov/stem_cells/ registry/current.htm) ( Fig. 2A) .
We routinely assess ES and primary cell cultures for telomere length since this parameter directly correlates with replicative lifespan in cultured somatic cells (Allsopp et al., 1992) . As expected, all hESC lines tested express active telomerase (data not shown) and have mean telomere lengths in the 8-20 kbp range, typical of other hESC lines and sperm (Figs. 2A, D) .
Copy number Variation in ESI cell lines
We evaluated CNVs in the ESI lines using two methods: SNPbased arrays (HumanCytoSNP-12, and GenomeStudio Genotyping Module, Illumina) and whole genome sequencebased methods (Complete Genomics, Inc.).
SNP-called CNV
The average spacing of this array (300K SNP) is approximately 10 kbp and as such, can be used to identify variants that span 50 kbp or larger. Call rates for all samples averaged N 99% (data not shown). We reviewed CNVs that had high confidence scores (N 100) as this cut-off consistently captured the same CNVs in technical replicates (data not shown). Using this sift, the majority of CNVs identified in the ESI lines were larger than 100 kb. Early passage cultures of the ESI lines typically displayed fewer than 5 highconfidence CNVs with sizes ranging from 0.2 to 2 Mbp (Fig. 3A) . These CNVs were found to be predominantly within regions previously annotated in databases of variance found in normal human genomes (Database of Genomic Variants (DGV); Zhang et al., 2006) . For example, a 1.59 Mbp CNV seen in early passage cultures of ESI017 covers a region in which both an increase and decrease in copy number is reported in DGV (Fig. 3B) . The total number of potentially affected genes in this analysis of the ESI lines ranged from 0 to 20 and similar CNVs and affected gene numbers were seen in early passages of the ES lines H1 and H9 (Fig. 3A) . The CNVs seen in early passage cultures of the hESC lines were retained in later passage cultures but new variance arose with longer-term culture. For example, later passage ESI049 cultures (P36) showed a loss of heterozygosity (LOH) of the q arm of Chr 17, while a substantial amplification of q17 was also seen in later passage (p49) H9 cultures (Fig. 3A) , alterations that have been reported in both cytogenetic and array-based assessments of long-term cultures of human cells (Laurent et al., 2011; Draper et al., 2004) . We reviewed the potential overlap of all CNVs with subsets of genes, including 169 identified tumor suppressor genes and 198 oncogenes (http://www.binfo.ncku.edu.tw/TAG/ GeneDoc.php) (Table S2 ). In these early passage cultures, we did not observe CNVs that overlapped with any of the tumor suppressor or oncogene exonic sequences (Fig. 3A) . As a further demonstration of this approach, we analyzed subsets of genes that would be predicted to be impactful on the development of a tissue-specific cellular therapeutics. We extracted over 70 genes from OMIM (http://www. ncbi.nlm.nih.gov/omim/) reported to be mutated in human genetic diseases affecting cartilage development, maintenance and disease propensity (Table S2) . Again, no early passage cultures had CNVs that affected the gene count for this set.
Genome sequence-called CNVs
Effectively, CNVs can be estimated by comparing readdepth calls to those expected from the reference genome (Methods). Sequence-called CNVs confirmed several of the SNP-called CNVs with the exception of those that were eliminated due to genome build formats (SNP data was Build 36, genome data was from Build 37), or from chromosomal locations not covered by SNPs in the array format (data not shown). The sequence-based CNV algorithms assess read depths on a 1 kbp scan window and thus can identify CNVs at finer resolution than the CytoSNP12 arrays used in this study. To provide a relevant metric for this analysis, we compared CNVs in the sequenced ESI cell lines with those identified in 46 genomes from normal human donors sequenced on the same platform (Complete Genomics, Table S3 ). The overall size distribution of CNVs was similar between ESI lines and human genome samples, with the majority of CNVs falling in the 5-20 kbp range (Fig. 4A) . The chromosomal distribution of CNVs in the ESI lines appeared relatively unbiased and did not differ in size or distribution from that of the normal genome samples (Fig. 4B) . Furthermore, the majority of CNVs detected by this analysis occurred in regions defined either as segmental duplication, or low complexity, such as LINE, SINE and LTR sequences and were annotated in the database of genomic variance (Table S4) .
Complete genome sequence
We performed complete genome re-sequencing of the 5 ESI lines using a commercial adaptation of the combinatorial probe anchor ligation (cPAL) chemistry and DNA nanoballs; variants were called and scored using a local de novo assembly methodology (Complete Genomics, Inc; Drmanac et al., 2010) . Re-sequencing maps raw reads to a reference genome (NCBI Build 37) and reports variance compared to the haploid genome reference. We concentrated our initial analysis on exonic and coding (cds) sequences as these are most typically disrupted in human genetic disease. Haploid read Table S4 ) is indicated. B: Circos diagram (Krzywinski et al., 2009) representing the distribution of CNVs identifies in on Chr 1 for ESI017 and 3 normal human genomes. Bar width is proportional to CNV size interval. Outer rim shows G-banding for Chr1.
coverage and percent genome coverage were similar to those reported previously while the % of fully called sequence for exonic and cds sequences was 96-97% (Table S5 ). Since our sequence analysis is compared only to the reference build, we again used genome sequences from normal donors (Table S3 ) sequenced using the identical platform for comparison of variant profiles. To identify potentially disruptive variants in the exonic regions of the genomes, we used ANNOVAR (Wang et al., 2010) an informatics software tool, to identify and sort potential sequence variants (Fig. 5) . In comparison to 46 normal human genomes analyzed using the same sequencing platform, the early passage ESI lines displayed a frequency of potentially disruptive exonic variations, including frame-shift insertion/deletions, nonsense substitutions, splice donor/acceptor changes and non-synonymous substitutions that fell within the normal genome range (Fig. 6) . We then asked whether potentially disruptive variants fell within important gene classes. Similar to the results seen in the complete genome exome, nonsynonymous substitutions were the predominant variants identified in the analysis of tumor suppressor genes (Table S2 ) (Fig. 6 ), however the impact of substitutions that do not directly alter coding sequence can be difficult to assess by informatics alone. Frameshift or nonsense mutations could be impactful in terms of tumor suppressor gene function and we identified a single frameshift variant affecting tumor suppressor genes in ESI017 (EGR1), ESI053 (AIM2) and ESI049 (COL18A1) (Fig. 6) . Two of these genes (EGR1, COL18A1) have been identified as loss of copy number variants in normal genomes (DGV; data not shown). This would suggest that even complete loss of a single copy of these genes may be less likely to be considered impactful. Similarly, the distribution of variance in a large collection of defined oncogenes (Table S2) showed similar substitution frequencies in ESC and normal genomes (Fig. 6) .
ABO, ApoE and HLA variants
Complete genome sequence can also serve to provide initial information on disease propensity alleles and transplantationrelated markers of cellular therapeutics. The ABO blood type is defined by the 3 alleles of the ABO gene (Fig. 7A) . A review of these in the sequence of the ESI lines showed unambiguous allele calls reflecting OO, AO and AA blood types. These were confirmed using a multiplex PCR assay Figure 5 Sequence variance analysis strategy. Sequence variants that differ from the reference build (NCBI Bld37) were assessed using a modified version of ANNOVAR (Wang et al., 2010) . SIFT (Ng and Henikoff, 2001 ) identifies and removes low impact variants. Exonic variants are then contrasted against specific gene sets. (Figs. 7C, S1 ). Given the significant impact of ApoE genotypes on cardiovascular and Alzheimer's disease propensities, we reviewed the ESI line genomes for the 3 major ApoE alleles (E2, E3, E4). The processed sequence suggested calls for cell lines ESI017 and 051 (Fig. 7A) , while half calls and no calls prevented the determination of the genotypes at the high confidence threshold for the remaining lines. A review of the evidence files for these genomes revealed a very low read depth across these positions (4-6 reads) (data not shown). We performed multi-plex PCR-based analysis of APOE alleles and confirmed the determination calls for the two lines and assigned ApoE genotypes for the remaining lines (Figs. 7B, S2) . None of the ESI lines, nor H1 and H9, carry the potentially deleterious ApoE4/E4 genotype. Similarly, sequence calls across the classical HLA loci were insufficient for unambiguous typing, as both the complex variance at these loci and issues of phase determination represent significant technical hurdles for this application. Amplification and re-sequencing of the genomic loci for the HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 genes provided allele calls for each cell line (Fig. 7D) . Three of the most frequently occurring HLA haplotypes in American populations (Maiers et al., 2007) are compatible with the observed phenotypes of ESI017 (A*01:01-B1*08:01C*07:02 DRB1*03:01), ESI035 (A*03:01-B*35:01C*04:01 DRB1*01:01), and ESI051, 053 (A*03:01-B*07:02C*07:02 DRB1*15:01).
Discussion
We report here a set of methodologies intended to provide a complete and thorough review of the genome integrity of cellular therapeutics. Our approach includes a review of the chromosomal integrity and for the first time, a careful review of the genome sequence integrity of cell lines derived using GMP-compliant processes and documentation. Importantly, we have compared the occurrence of variance in terms of type, size and distribution and conclude that at early passage, hESCs are entirely consistent with variance seen in normal human genomes. Given the importance of cellular integrity for cell therapeutic applications, reviewing the genome and sequence integrity for these same products will likely become a standard requirement for nonautologous therapeutics.
Extended in vitro expansion of hESC and other cultured human cells most often results in large scale chromosomal abnormalities, as has been documented using cytological methods (Draper et al., 2004 ) and more recently, SNP and Figure 6 Summary of exonic sequence variants from analysis strategy (Fig. 5) . Sequence variants of the indicated type were scored for each ESI line in comparison to a range (or average) of the same variant types in 46 normal human genomes (* Table S3 ), including total exonic variants, exonic variants found in tumor suppressor genes (Fig. S2) , and exonic variants found in protooncogenes (Fig.  S2) . For frameshift and stopgain (nonsense) variants in the ESI lines, the affected genes are indicated.
FISH-based methodologies (Laurent et al., 2011; Caisander et al., 2006) . We confirm here the propensity of later stage cultures to show examples of classical karyotypic abnormalities, such as chromosome 12 and 17 aneuploidy. Importantly, cytological methodologies can detect these variances even when present in a small minority of cells in a culture and provide early evidence of cultures that begun to drift (Meisner and Johnson, 2008) . The application of multiple FISH probes should allow an even sharper detection of the emergence of common chromosomal variants in cultured populations.
Array and complete genomic hybridization-based methods are now being used to detect deletions and amplifications that are considerably shorter than the resolution of cytogenetic techniques. Our data provides additional evidence of accrual of CNVs with extended culture, potentially as a result of replicative stress and culture adaptation (Narva et al., 2010; Baker et al., 2007) . We applied two orthogonal methods (SNP array and sequence-based detection) to identify these variances. Replicate analyses using arraybased methods showed good reproducibility for high confidence CNVs, while sequence-based methods confirmed some, but not all CNVs detected by arrays, suggesting that alternate methods can provide complementary information. Importantly, the vast majority of CNVs identified in these early passage cultures have been previously described in databases that curate CNVs in normal human genomes (Iafrate et al., 2004) and these sequence intervals typically show low sequence complexity, as demonstrated by the preponderance of LINE elements and regions of segmental duplication in these intervals. Sequence-based detection of CNVs allowed for the direct comparison of hESC lines to normal human genomes and by all measure of size, distribution and affected genes, CNVs found in these early passage ES cultures were entirely within the range of normal genome variation.
Complete genome sequencing methodologies and annotation provide sequence resolution that allows for the initial detection and cataloging of variance, although the accuracy or A B D C Figure 7 Evaluation of ABO, ApoE and HLA allelic variants. A: Genome sequence was evaluated directly for ABO and ApoE allele status. ABO alleles could be called unambiguously from the sequence reads. ApoE alleles for ESI 017 and 051 were called, alleles for ESI035, 049 and 053 were not called due to low read coverage. B: TaqMan assay results for ApoE alleles (E2, E3, E4) (Fig. S2) . C: Multiplex PCR assay results for ABO blood type alleles (Fig. S1) . D: HLA typing of 10 major HLA alleles. Genomic DNA was amplified across 10 major HLA alleles and re-sequenced.
completeness of calling a diploid genome is limited by the requirement for relatively deep sequence coverage. Clearly, orthogonal methods that confirm or complete sequence-based variance determinations remain a necessity. We confined our initial analyses to variance that could reliably be predicted to affect the expression of gene products from protein-encoding genes.
As opposed to iPS cell studies, where de novo mutations that have been cataloged between progenitor and iPS derivatives (Gore et al., 2011) , hESC lines have not yet been directly compared to the genomes of the donor embryos (nor can they be compared to the parental IVF donors). However we show that by all measures of nucleotide-level variance, these early passage ES lines show variance that is entirely within the range seen in normal human genomes. hESC lines have been shown to have effective means to ensure genome integrity, such as enhanced apoptosis of mutated cells and enhanced mitotic recombination (Filion et al., 2009; Hong et al., 2007) , however maintenance of this integrity is challenged continually in long term in vitro cultures. The analysis of genome and sequence integrity can be applied to select an appropriate progenitor line, and should then be repeated at regular intervals during the expansion and derivation of cell populations.
Further focusing these analyses on gene sets that are of specific concern for developing therapeutic products (tumor suppressor/oncogenes), we see no appreciable difference in the variance found in hESC vs. normal human genomes. This same type of analysis can be applied to inherited disease genes (OMIM), disease propensity alleles (GWAS (Hindorff et al., 2009) ), or mutation databases (HGMD) (Stenson et al., 2009) and would then allow for the selection of cell lines that lack deleterious variants or mutations. The evaluation of APOE alleles is a prime example of this approach. Although the direct cellular mechanisms by which the E4/E4 allelic combination contributes to late onset Alzheimer's disease are likely complex, clearly avoiding this combination when choosing a cell line for developing neuronal applications would seem prudent.
We demonstrate here that the evaluation of transplantationrelated alleles, such as ABO and HLA can also be evaluated directly from sequence data and this can allow for the selection of specific cell lines for specific therapeutic applications (e.g. Blood type OO for the development of erythrocyte progenitors). In spite of high reported accuracy of the cPAL sequencing methods (Drmanac et al., 2010) , orthogonal methods that confirm or complete sequence-based variance remain a necessity until an expected clinical genome quality is achieved in this rapidly developing field.
Experimental procedures Cell culture
The ESC lines ESI017, 035, 049, 051 and 053 (Crook et al., 2007) and H1, H9 were cultured from research-grade cell banks on matrigel-coated culture plastic (Ludwig et al., 2006; Rosler et al., 2004) . Briefly, hESC lines were cultured on tissue culture plastic coated with Growth Factor Reduced Matrigel (Becton-Dickenson, Inc) in mTeSR1™ medium (Stem Cell Technologies, Inc.) hESC were passaged weekly (1:3 or 1:4 split ratio) using 5 mM EDTA (Invitrogen, Inc.) or Accutase (Innovative Cell Technologies, Inc.), and supplemented with 10 μM of Rock Inhibitor, Y-27632 (Tocris Bioscience) at plating. FACS-based assessment of markers was performed using an Accuri C6 Flow Cytometer with CSampler and CFlow Sampler Software (Accuri) and antibodies listed in Table S1 .
Cytogenetic analyses
Cultures of ESI lines were evaluated at Cell Line Genetics, Inc. (Madison, WI) for G-banded karyotype analysis and FISH assessment of interphase nuclei using probes for ETV6 (12p) and the chromosome 17 centromere as described (Meisner and Johnson, 2008) .
DNA preparation
Total genomic DNA was prepared from by using the QIAGEN Blood & Cell Culture DNA Kit (Qiagen).
STR fingerprinting
Analysis of genomic DNA for 15 STR loci plus Amelogelin was performed at Cell Line Genetics, Inc. (Madison WI).
TRF analysis
Mean TRF lengths were determined by non-radioactive Southern blotting using the TeloTAGGG Telomere Length Assay kit (Roche).
SNP array CNV analysis
Genomic DNA samples were analyzed at the Biomedical Genomics Center usingCytoSNP12 BeadChip kits (Illumina) using the BeadStudio2009.2 software (Illumina). Call rates were greater than 99.1%. Normalized intensity ratios (logR), B allele frequencies (BAF) and CNVs were extracted using the GenomeStudio Genotyping Module (Illumina). CNVs with confidence scores greater than or equal to 100 were included in subsequent analyses.
Genome sequencing
Genomic DNA samples were analyzed at Complete Genomics, Inc. (Mountain View, CA). Paired end library preparation and sequence-by-ligation methods were applied as described (Drmanac et al., 2010) . Reads were mapped to the NCBI reference genome (Build 37) and data for each genome sample were provided as listing of sequence variants relative to the reference genome.
Genome sequence CNV analysis
The "cnvSegmentsBeta files" from the Complete Genomics data files were first filtered to remove potential CNVs that were annotated as having "invariant counts": (non diploid copy number that is invariable in normal genomes), or "hypervariable counts" (highly variable in normal human genomes) or were from mitochondrial sequence. The remaining calls indicating an increase or decrease from the reference copy number were tabulated.
